Literature DB >> 9273913

Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries.

G Corrao1, P Ferrari, A Zambon, P Torchio.   

Abstract

OBJECTIVE: A striking reduction of alcohol-related problems, such as liver cirrhosis death rates, has been observed in many western countries in recent years. It might be expected that these declines are accompanied by a lagged reduction in per capita alcohol consumption, since many years of intake are required for cirrhosis of the liver to develop (lag theory). The main aim of this study is to verify the validity of the lag theory, taking as target populations those resident in European countries.
METHOD: Changes in liver cirrhosis death rates in 22 European countries between 1970 and 1089 were regressed onto changes in per capita alcohol consumption (1961-89) to evaluate the latency period between trends of these variables.
RESULTS: Eastern countries had a latency period between trends in alcohol consumption and in mortality rates of many years, whereas in northern, western and southern Europe cirrhosis mortality rates were explained by their relationship with per capita alcohol consumption, which lagged a few years. In some countries, an immediate contemporary appearance of the two phenomena was observed.
CONCLUSIONS: These results suggest that the lag theory cannot fully explain the relationship between changing alcohol consumption and cirrhosis mortality and that other factors, such as alcoholism treatment rates, are involved in the wide geographical variability of the latency periods.

Entities:  

Mesh:

Year:  1997        PMID: 9273913     DOI: 10.15288/jsa.1997.58.486

Source DB:  PubMed          Journal:  J Stud Alcohol        ISSN: 0096-882X


  13 in total

1.  Definition, epidemiology and magnitude of alcoholic hepatitis.

Authors:  Sarpreet Basra; Bhupinderjit S Anand
Journal:  World J Hepatol       Date:  2011-05-27

2.  Alcohol consumption and gender in the 20th century: the case of Switzerland.

Authors:  M Bopp; G Gmel
Journal:  Soz Praventivmed       Date:  1999

Review 3.  Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease.

Authors:  Shane J Mills; Stephen A Harrison
Journal:  Curr Gastroenterol Rep       Date:  2005-02

4.  Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.

Authors:  Hauke S Heinzow; Philipp Lenz; Michael Köhler; Frank Reinecke; Hansjörg Ullerich; Wolfram Domschke; Dirk Domagk; Tobias Meister
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

5.  Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption.

Authors:  Guoxiang Xie; Wei Zhong; Houkai Li; Qiong Li; Yunping Qiu; Xiaojiao Zheng; Huiyuan Chen; Xueqing Zhao; Shucha Zhang; Zhanxiang Zhou; Steven H Zeisel; Wei Jia
Journal:  FASEB J       Date:  2013-05-24       Impact factor: 5.191

6.  Alcohol and drug treatment systems in public health perspective: mediators and moderators of population effects.

Authors:  Thomas F Babor; Kerstin Stenius; Anders Romelsjo
Journal:  Int J Methods Psychiatr Res       Date:  2008-06       Impact factor: 4.035

Review 7.  Liver fibrosis markers in alcoholic liver disease.

Authors:  Lech Chrostek; Anatol Panasiuk
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

8.  Chronic ethanol consumption alters mammalian gastrointestinal content metabolites.

Authors:  Guoxiang Xie; Wei Zhong; Xiaojiao Zheng; Qiong Li; Yunping Qiu; Houkai Li; Huiyuan Chen; Zhanxiang Zhou; Wei Jia
Journal:  J Proteome Res       Date:  2013-06-14       Impact factor: 4.466

Review 9.  The impact of obesity and metabolic syndrome on alcoholic liver disease.

Authors:  Dian J Chiang; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2013-10-24       Impact factor: 6.126

10.  KASL clinical practice guidelines: management of alcoholic liver disease.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2013-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.